As major U.S. indices rebound with solid weekly gains, investors are turning their attention to various opportunities within the market. Penny stocks, despite their somewhat outdated name, continue to offer intriguing prospects for those interested in smaller or newer companies. These stocks can provide a mix of affordability and growth potential when paired with strong financials, making them worth considering for investors seeking under-the-radar opportunities.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Waterdrop (WDH) | $1.74 | $625.68M | ✅ 4 ⚠️ 0 View Analysis > |
| Vasta Platform (VSTA) | $4.23 | $341.7M | ✅ 4 ⚠️ 1 View Analysis > |
| WM Technology (MAPS) | $0.902 | $160.27M | ✅ 4 ⚠️ 1 View Analysis > |
| Performance Shipping (PSHG) | $1.80 | $22.75M | ✅ 4 ⚠️ 2 View Analysis > |
| Tuniu (TOUR) | $0.9326 | $90.93M | ✅ 3 ⚠️ 2 View Analysis > |
| Riverview Bancorp (RVSB) | $4.88 | $104.04M | ✅ 3 ⚠️ 1 View Analysis > |
| BAB (BABB) | $0.9144 | $6.54M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.93 | $93.69M | ✅ 3 ⚠️ 3 View Analysis > |
| Resources Connection (RGP) | $4.64 | $156.36M | ✅ 3 ⚠️ 1 View Analysis > |
| TETRA Technologies (TTI) | $3.89 | $519.79M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 415 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
C4 Therapeutics (CCCC)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates to degrade disease-causing proteins, with a market cap of $139.17 million.
Operations: C4 Therapeutics, Inc. does not report distinct revenue segments as it is a clinical-stage biopharmaceutical company.
Market Cap: $139.17M
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company with a market cap of US$139.17 million, is pre-revenue and has been experiencing increased losses, reporting a net loss of US$26.02 million for the recent quarter. Despite having sufficient cash runway for 1.9 years and no debt obligations, its share price remains highly volatile and it has been removed from several Russell indices recently. The management team is experienced with an average tenure of 2.1 years, but the company is not expected to achieve profitability in the next three years despite forecasts of significant revenue growth annually.
- Click here and access our complete financial health analysis report to understand the dynamics of C4 Therapeutics.
- Evaluate C4 Therapeutics' prospects by accessing our earnings growth report.
Vimeo (VMEO)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Vimeo, Inc., along with its subsidiaries, offers video software solutions both in the United States and internationally, with a market cap of approximately $697.64 million.
Operations: The company generates revenue from its Internet Software & Services segment, totaling $415.40 million.
Market Cap: $697.64M
Vimeo, Inc., with a market cap of US$697.64 million, reported Q2 2025 earnings of US$104.65 million, slightly up from the previous year. However, net income fell to US$6.29 million from US$10.12 million a year ago, reflecting challenges in maintaining profit margins which dropped to 3.1% from 7.7%. Despite being debt-free and trading at a significant discount to its estimated fair value, Vimeo's recent negative earnings growth poses concerns amidst management changes and an inexperienced board with an average tenure of 2.2 years. The company was recently added to several Russell indices but has yet to capitalize on this momentum fully.
- Get an in-depth perspective on Vimeo's performance by reading our balance sheet health report here.
- Examine Vimeo's earnings growth report to understand how analysts expect it to perform.
CS Disco (LAW)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: CS Disco, Inc. offers cloud-native and AI-powered legal solutions for various legal processes, including ediscovery and case management, with a market cap of $254.99 million.
Operations: CS Disco, Inc. has not reported any specific revenue segments.
Market Cap: $254.99M
CS Disco, Inc., with a market cap of US$254.99 million, recently reported Q2 2025 earnings of US$38.11 million, showing modest revenue growth but remaining unprofitable with a net loss of US$10.81 million. Despite this, the company raised its fiscal year 2025 revenue guidance to between US$148 million and US$158 million and launched DISCO Auto Review in the EU/U.K., enhancing its AI-powered legal solutions. While CS Disco is debt-free and has sufficient cash runway for over three years, significant insider selling and an inexperienced management team may present challenges moving forward amidst ongoing executive changes.
- Jump into the full analysis health report here for a deeper understanding of CS Disco.
- Assess CS Disco's future earnings estimates with our detailed growth reports.
Next Steps
- Jump into our full catalog of 415 US Penny Stocks here.
- Interested In Other Possibilities? Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Vimeo might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com